SI2361090T1 - Sestavki za zdravljenje centralno izzvanih slabosti in bruhanja - Google Patents

Sestavki za zdravljenje centralno izzvanih slabosti in bruhanja

Info

Publication number: SI2361090T1
Authority: SI; Slovenia
Prior art keywords: vomiting; compositions; centrally mediated; treating; nausea
Prior art date: 2009-11-18

Application number

SI201030688T

Other languages

English (en)

Inventor

Fabio Trento

Sergio Cantoreggi

Giorgia Rossi

Roberta Cannella

Daniele Bonadeo

Riccardo Braglia

Original Assignee

Helsinn Healthcare S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-18

Filing date

2010-11-18

Publication date

2014-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2361090(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-18 Application filed by Helsinn Healthcare S.A. filed Critical Helsinn Healthcare S.A.

2014-09-30 Publication of SI2361090T1 publication Critical patent/SI2361090T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Paints Or Removers (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Plant Substances (AREA)

SI201030688T 2009-11-18 2010-11-18 Sestavki za zdravljenje centralno izzvanih slabosti in bruhanja SI2361090T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US26247009P	2009-11-18	2009-11-18
US38270910P	2010-09-14	2010-09-14
EP10805301.8A EP2361090B1 (en)	2009-11-18	2010-11-18	Compositions for treating centrally mediated nausea and vomiting
PCT/IB2010/003106 WO2011061622A1 (en)	2009-11-18	2010-11-18	Compositions for treating centrally mediated nausea and vomiting

Publications (1)

Publication Number	Publication Date
SI2361090T1 true SI2361090T1 (sl)	2014-09-30

Family

ID=43608757

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201030688T SI2361090T1 (sl)	2009-11-18	2010-11-18	Sestavki za zdravljenje centralno izzvanih slabosti in bruhanja
SI201031291T SI2722045T1 (sl)	2009-11-18	2010-11-18	Sestavki za zdravljenje centralno izzvane slabosti in bruhanja

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI201031291T SI2722045T1 (sl)	2009-11-18	2010-11-18	Sestavki za zdravljenje centralno izzvane slabosti in bruhanja

Country Status (39)

Country	Link
US (1)	US12042494B2 (sl)
EP (3)	EP2361090B1 (sl)
JP (1)	JP5890780B2 (sl)
KR (1)	KR101615108B1 (sl)
CN (6)	CN106421793B (sl)
AP (1)	AP3083A (sl)
AU (1)	AU2010320598B2 (sl)
BR (1)	BR112012011485B1 (sl)
CA (1)	CA2778301C (sl)
CL (1)	CL2012001276A1 (sl)
CO (1)	CO6551693A2 (sl)
CR (1)	CR20120216A (sl)
CU (1)	CU24048B1 (sl)
CY (1)	CY1118062T1 (sl)
DK (2)	DK2361090T3 (sl)
DO (1)	DOP2012000138A (sl)
EA (1)	EA026815B1 (sl)
EC (1)	ECSP12011907A (sl)
ES (4)	ES2595077T3 (sl)
GE (1)	GEP20156226B (sl)
GT (1)	GT201200156A (sl)
HK (2)	HK1214147A1 (sl)
HR (3)	HRP20140759T1 (sl)
HU (1)	HUE029677T2 (sl)
IL (1)	IL219576A (sl)
LT (1)	LT2722045T (sl)
MA (1)	MA33810B1 (sl)
MX (1)	MX2012005347A (sl)
MY (1)	MY159393A (sl)
NI (1)	NI201200090A (sl)
NZ (1)	NZ599439A (sl)
PE (1)	PE20121483A1 (sl)
PL (3)	PL2722045T3 (sl)
PT (2)	PT2361090E (sl)
RS (2)	RS53491B1 (sl)
SI (2)	SI2361090T1 (sl)
SM (1)	SMT201400112B (sl)
TN (1)	TN2012000170A1 (sl)
WO (1)	WO2011061622A1 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2722045B1 (en)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions for treating centrally mediated nausea and vomiting
SI2361090T1 (sl)	2009-11-18	2014-09-30	Helsinn Healthcare S.A.	Sestavki za zdravljenje centralno izzvanih slabosti in bruhanja
US9782397B2 (en)	2011-07-04	2017-10-10	Irbm Science Park S.P.A.	Treatment of corneal neovascularization
HUE030811T2 (hu) *	2011-10-18	2017-05-29	Helsinn Healthcare Sa	Netupitant és palonosetron terápiás kombinációi
US8426450B1 (en)	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
US9403772B2 (en)	2011-11-29	2016-08-02	Helsinn Healthcare Sa	4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
CN103520725B (zh) *	2012-07-05	2017-10-24	海思科医药集团股份有限公司	一种治疗呕吐的药物组合物
CN106902086B (zh) *	2015-12-23	2020-10-20	江苏恒瑞医药股份有限公司	一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) *	2016-11-01	2016-12-14	Acacia Pharma Ltd	method
GB201702250D0 (en)	2017-02-10	2017-03-29	Acacia Pharma Ltd	Method
CN108721214B (zh) *	2017-04-14	2020-06-16	和龙	奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) *	2017-05-15	2018-11-23	和龙	奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) *	2017-07-04	2019-01-15	南京诺瑞特医药科技有限公司	含有奈妥吡坦的微乳制剂
WO2019099883A1 (en) *	2017-11-17	2019-05-23	Vanda Pharmaceuticals Inc.	Method of treatment of gastrointestinal diseases with tradipitant
CA3089656A1 (en) *	2018-02-02	2019-08-08	Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro)	Oral formulations and uses thereof
EP4385497A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Fixed dose combination comprising netupitant and palonosetron
WO2024126398A1 (en)	2022-12-12	2024-06-20	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Fixed dose combination comprising netupitant and palonosetron
WO2024126408A1 (en)	2022-12-12	2024-06-20	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL166272B1 (pl)	1989-11-28	1995-04-28	Syntex Inc	Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
US5510486A (en)	1994-07-26	1996-04-23	Syntex (U.S.A.) Inc.	Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en)	1995-11-10	2001-10-02	The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland	Calixarenes and their use for sequestration of metals
EP1394150B1 (en)	1999-02-24	2011-01-19	F. Hoffmann-La Roche AG	4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
ATE400556T1 (de)	2000-07-14	2008-07-15	Hoffmann La Roche	N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
DK1349541T3 (da)	2000-12-14	2007-01-08	Hoffmann La Roche	Selvemulgerende lipidmatrix (SELM)
CA2505990C (en)	2002-11-15	2009-05-19	Helsinn Healthcare S.A.	Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en)	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formations of balloonosterone
MY143789A (en)	2003-02-18	2011-07-15	Helsinn Healthcare Sa	Use of palonosetron treating post- operative nausea and vomiting
US20050004155A1 (en) *	2003-04-08	2005-01-06	Boyd Thomas A.	Use of methylnaltrexone to treat irritable bowel syndrome
CN101128189A (zh)	2005-02-25	2008-02-20	弗·哈夫曼-拉罗切有限公司	药物物质分散性改善的片剂
US7479312B2 (en)	2005-07-07	2009-01-20	Konica Minolta Opto, Inc.	Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
MEP6808A (xx) *	2006-02-23	2010-02-10	Lundbeck & Co As H	Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
AU2007308378B2 (en) *	2006-10-24	2013-02-21	Helsinn Healthcare S.A.	Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
WO2009005673A1 (en) *	2007-06-28	2009-01-08	Schering Corporation	Anti-igf1r
MX2010006854A (es) *	2007-12-18	2010-09-09	Schering Corp	Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
SI2361090T1 (sl)	2009-11-18	2014-09-30	Helsinn Healthcare S.A.	Sestavki za zdravljenje centralno izzvanih slabosti in bruhanja

2010
- 2010-11-18 SI SI201030688T patent/SI2361090T1/sl unknown
- 2010-11-18 PT PT108053018T patent/PT2361090E/pt unknown
- 2010-11-18 EP EP10805301.8A patent/EP2361090B1/en active Active
- 2010-11-18 PT PT141516831T patent/PT2722045T/pt unknown
- 2010-11-18 EP EP14151676.5A patent/EP2727590B1/en active Active
- 2010-11-18 PL PL14151683T patent/PL2722045T3/pl unknown
- 2010-11-18 DK DK10805301.8T patent/DK2361090T3/da active
- 2010-11-18 KR KR1020127015676A patent/KR101615108B1/ko active IP Right Grant
- 2010-11-18 CN CN201610795827.5A patent/CN106421793B/zh active Active
- 2010-11-18 MX MX2012005347A patent/MX2012005347A/es active IP Right Grant
- 2010-11-18 GE GEAP201012752A patent/GEP20156226B/en unknown
- 2010-11-18 AU AU2010320598A patent/AU2010320598B2/en active Active
- 2010-11-18 EA EA201290356A patent/EA026815B1/ru active Protection Beyond IP Right Term
- 2010-11-18 EP EP14151678.1A patent/EP2722044B1/en active Active
- 2010-11-18 RS RSP20140423 patent/RS53491B1/en unknown
- 2010-11-18 DK DK14151683.1T patent/DK2722045T3/en active
- 2010-11-18 CN CN201610797549.7A patent/CN106512010A/zh active Pending
- 2010-11-18 PL PL10805301T patent/PL2361090T3/pl unknown
- 2010-11-18 SI SI201031291T patent/SI2722045T1/sl unknown
- 2010-11-18 ES ES14151683.1T patent/ES2595077T3/es active Active
- 2010-11-18 AP AP2012006278A patent/AP3083A/xx active
- 2010-11-18 PE PE2012000686A patent/PE20121483A1/es active IP Right Grant
- 2010-11-18 RS RS20160833A patent/RS55206B1/sr unknown
- 2010-11-18 BR BR112012011485-9A patent/BR112012011485B1/pt active IP Right Grant
- 2010-11-18 LT LTEP14151683.1T patent/LT2722045T/lt unknown
- 2010-11-18 CN CN201610795817.1A patent/CN107050455B/zh active Active
- 2010-11-18 CN CN201510047631.3A patent/CN104856999A/zh active Pending
- 2010-11-18 CA CA2778301A patent/CA2778301C/en active Active
- 2010-11-18 ES ES14151678.1T patent/ES2623503T3/es active Active
- 2010-11-18 MY MYPI2012002073A patent/MY159393A/en unknown
- 2010-11-18 PL PL14151678T patent/PL2722044T3/pl unknown
- 2010-11-18 NZ NZ599439A patent/NZ599439A/en unknown
- 2010-11-18 HU HUE14151683A patent/HUE029677T2/hu unknown
- 2010-11-18 CN CN2010800521070A patent/CN102655864A/zh active Pending
- 2010-11-18 ES ES14151676.5T patent/ES2559475T3/es active Active
- 2010-11-18 ES ES10805301.8T patent/ES2494015T3/es active Active
- 2010-11-18 CN CN201510046972.9A patent/CN104856998A/zh active Pending
- 2010-11-18 JP JP2012539433A patent/JP5890780B2/ja active Active
- 2010-11-18 WO PCT/IB2010/003106 patent/WO2011061622A1/en active Application Filing
2012
- 2012-04-13 TN TNP2012000170A patent/TN2012000170A1/en unknown
- 2012-04-26 CR CR20120216A patent/CR20120216A/es unknown
- 2012-05-03 IL IL219576A patent/IL219576A/en active IP Right Grant
- 2012-05-10 NI NI201200090A patent/NI201200090A/es unknown
- 2012-05-15 DO DO2012000138A patent/DOP2012000138A/es unknown
- 2012-05-16 CL CL2012001276A patent/CL2012001276A1/es unknown
- 2012-05-17 EC ECSP12011907 patent/ECSP12011907A/es unknown
- 2012-05-18 CU CU2012000078A patent/CU24048B1/es active IP Right Grant
- 2012-05-18 GT GT201200156A patent/GT201200156A/es unknown
- 2012-05-18 CO CO12082329A patent/CO6551693A2/es not_active Application Discontinuation
- 2012-06-11 MA MA34953A patent/MA33810B1/fr unknown
2014
- 2014-08-11 HR HRP20140759AT patent/HRP20140759T1/hr unknown
- 2014-08-18 SM SM201400112T patent/SMT201400112B/xx unknown
2016
- 2016-02-24 HK HK16102109.6A patent/HK1214147A1/zh unknown
- 2016-02-24 HK HK16102110.3A patent/HK1214148A1/zh unknown
- 2016-10-05 CY CY20161100991T patent/CY1118062T1/el unknown
- 2016-10-05 HR HRP20161277TT patent/HRP20161277T1/hr unknown
2017
- 2017-03-14 HR HRP20170419TT patent/HRP20170419T1/hr unknown
2022
- 2022-12-16 US US18/082,737 patent/US12042494B2/en active Active

Also Published As

Publication number	Publication date
EP2727590B1 (en)	2015-10-21
CY1118062T1 (el)	2017-06-28
GEP20156226B (en)	2015-01-26
CA2778301C (en)	2016-06-14
HK1214147A1 (zh)	2016-07-22
JP2013511507A (ja)	2013-04-04
AU2010320598A1 (en)	2012-06-14
DK2722045T3 (en)	2016-10-24
AP2012006278A0 (en)	2012-06-30
MY159393A (en)	2016-12-30
DOP2012000138A (es)	2012-11-15
CO6551693A2 (es)	2012-10-31
RS55206B1 (sr)	2017-01-31
KR20120101456A (ko)	2012-09-13
ES2494015T3 (es)	2014-09-12
MA33810B1 (fr)	2012-12-03
BR112012011485A2 (pt)	2018-04-03
ES2559475T3 (es)	2016-02-12
EP2727590A1 (en)	2014-05-07
AU2010320598B2 (en)	2016-06-16
SMT201400112B (it)	2014-11-10
PT2361090E (pt)	2014-09-03
CR20120216A (es)	2012-07-24
EP2361090B1 (en)	2014-05-21
MX2012005347A (es)	2012-08-03
ECSP12011907A (es)	2012-10-30
NZ599439A (en)	2014-06-27
EA026815B1 (ru)	2017-05-31
HUE029677T2 (hu)	2017-03-28
WO2011061622A1 (en)	2011-05-26
CU24048B1 (es)	2014-12-26
PT2722045T (pt)	2016-10-18
NI201200090A (es)	2012-11-13
PL2722045T3 (pl)	2017-03-31
CN107050455B (zh)	2020-09-29
HRP20161277T1 (hr)	2016-11-18
DK2361090T3 (da)	2014-08-25
CA2778301A1 (en)	2011-05-26
LT2722045T (lt)	2016-09-26
CN104856999A (zh)	2015-08-26
IL219576A0 (en)	2012-06-28
US12042494B2 (en)	2024-07-23
HK1214148A1 (zh)	2016-07-22
AP3083A (en)	2015-01-31
SI2722045T1 (sl)	2017-02-28
RS53491B1 (en)	2015-02-27
EP2361090A1 (en)	2011-08-31
EP2722044A1 (en)	2014-04-23
CN102655864A (zh)	2012-09-05
EP2722044B1 (en)	2017-01-04
ES2595077T3 (es)	2016-12-27
GT201200156A (es)	2014-03-27
PL2722044T3 (pl)	2017-08-31
ES2623503T3 (es)	2017-07-11
PL2361090T3 (pl)	2014-10-31
CL2012001276A1 (es)	2012-12-07
CN107050455A (zh)	2017-08-18
KR101615108B1 (ko)	2016-05-12
HRP20170419T1 (hr)	2017-06-02
HRP20140759T1 (hr)	2014-10-24
CU20120078A7 (es)	2012-10-15
IL219576A (en)	2017-08-31
PE20121483A1 (es)	2012-12-02
US20230263799A1 (en)	2023-08-24
CN106512010A (zh)	2017-03-22
JP5890780B2 (ja)	2016-03-22
EA201290356A1 (ru)	2012-12-28
CN104856998A (zh)	2015-08-26
CN106421793B (zh)	2023-06-16
BR112012011485B1 (pt)	2021-06-29
CN106421793A (zh)	2017-02-22
TN2012000170A1 (en)	2013-12-12

Publication	Publication Date	Title
HK1214147A1 (zh)	2016-07-22	用於治療中樞介導的噁心及嘔吐的組合物及方法
IL245734A0 (en)	2016-06-30	Methods and preparations to prevent abuse
EP2473042A4 (en)	2013-05-22	METHODS AND COMPOSITIONS FOR DESTROYING BIOFILM USING COMPOUNDS DERIVED FROM CHITOSAN
IL215932A0 (en)	2011-12-29	Compositions and methods for treating burns
EP2722045A3 (en)	2014-05-07	Compositions for treating centrally mediated nausea and vomiting
IL210097A0 (en)	2011-02-28	Compositions and methods for treating unfluenza
EP2504428A4 (en)	2013-09-25	METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
EP2429584A4 (en)	2013-02-20	TREATMENT PROCEDURE AND COMPOSITIONS
GB0903299D0 (en)	2009-04-08	Composition and methods
GB0912468D0 (en)	2009-08-26	Composition and method
EP2490536A4 (en)	2013-04-17	COMPOSITION AND METHOD
EP2294198A4 (en)	2011-10-19	METHODS AND COMPOSITIONS FOR ENHANCING PLANTS
GB0901494D0 (en)	2009-03-11	Compositions and Methods
EP2393506A4 (en)	2012-08-01	METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES
PL2263454T3 (pl)	2017-07-31	Kompozycja uzdatniająca
IL217764A0 (en)	2012-03-29	Methods and compositions for treating leukemia
EP2501672A4 (en)	2013-05-01	COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS
GB0901667D0 (en)	2009-03-11	Composition and method
ZA201203174B (en)	2013-02-27	Compositions for treating centrally mediated nausea and vomiting
HK1166017A1 (en)	2012-10-19	Compositions and methods for causing neurite outgrowth
GB0912714D0 (en)	2009-08-26	Composition and process
GB0907616D0 (en)	2009-06-10	Methods and compositions
GB0908498D0 (en)	2009-06-24	Compositions and methods
GB0909720D0 (en)	2009-07-22	Compositions and methods
IL219215A0 (en)	2012-06-28	Compositions and methods for treating aspergillosis